ENDRA Life Sciences Inc. — Director's Dealing 2017

May 16, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2017-05-08

Reporting Person: Michelon Francois Roger (Director, Chief Executive Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options	$10.01	2020-07-01	Common Stock (35498)		Direct
Convertible Promissory Note	$1.40	2017-05-12	Common Stock ()		Direct

Footnotes

F1: These Stock Options became exercisable as to 11,833 shares of Common Stock on July 1, 2016 and become exercisable as to the remaining 23,667 shares in two equal installments on July 1, 2017 and July 1, 2018.

F2: The principal amount of, and accrued interest on, the Convertible Promissory Note is convertible into shares of Common Stock of the Issuer at a conversion price of $1.40 per share immediately prior to the consummation of the Issuer's initial public offering.